Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32747012
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
The effects of renin-angiotensin system inhibitors (RASI) in coronavirus disease
(COVID-19) with hypertension: A retrospective, single-center trial
#MMPMID32747012
Cui H
; Wu F
; Fan Z
; Cheng X
; Cheng J
; Fan M
Med Clin (Barc)
2020[Oct]; 155
(7
): 295-298
PMID32747012
show ga
INTRODUCTION AND OBJECTIVE: A recent outbreak of coronavirus disease 2019
(COVID-19) occurs in the worldwide. Angiotensin-converting enzyme 2 (ACE2) can
mediate coronavirus entry into host cells. Therefore, renin-angiotensin system
inhibitors (RASI) were suspected of contributing to the increase of coronavirus
infection. We aimed to analyze the effects of RASI in COVID-19 patients with
hypertension. PATIENTS AND METHOD: In this retrospective, single-center study, 27
COVID-19 patients with hypertension, who were admitted to the Shanghai Public
Health Clinical Center from January 25, 2020 to January 31, 2020, were analyzed
for clinical features, laboratory parameters, medications and the length of stay.
All the patients were given antiviral and antihypertension treatment, of which 14
patients were treated with RASI and 13 patients without RASI. RESULTS: Comparing
the two groups, we did not found statistically significant differences in
clinical symptoms and laboratory tests. Furthermore, cough was not aggravated.
CONCLUSIONS: Through the analysis of this small sample, RASI could be deemed safe
and effective to control high blood pressure of COVID-19 patients. Further
analysis with a larger sampling size is required to explore the underlying
mechanisms.
|*Betacoronavirus
[MESH]
|Adult
[MESH]
|Aged
[MESH]
|Aged, 80 and over
[MESH]
|Angiotensin-Converting Enzyme Inhibitors/*adverse effects/therapeutic use
[MESH]
free
free
free
